- Home
- TOPS vs RLYB Comparison
TOPS vs RLYB Comparison
Compare TOPS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- RLYB
- Stock Information
- Founded
- TOPS 2000
- RLYB 2018
- Country
- TOPS Greece
- RLYB United States
- Employees
- TOPS N/A
- RLYB N/A
- Industry
- TOPS Marine Transportation
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- RLYB Health Care
- Exchange
- TOPS Nasdaq
- RLYB Nasdaq
- Market Cap
- TOPS 27.2M
- RLYB 22.0M
- IPO Year
- TOPS 2004
- RLYB 2021
- Fundamental
- Price
- TOPS $5.98
- RLYB $0.50
- Analyst Decision
- TOPS
- RLYB Hold
- Analyst Count
- TOPS 0
- RLYB 3
- Target Price
- TOPS N/A
- RLYB $15.00
- AVG Volume (30 Days)
- TOPS 14.5K
- RLYB 604.0K
- Earning Date
- TOPS 08-19-2025
- RLYB 08-07-2025
- Dividend Yield
- TOPS N/A
- RLYB N/A
- EPS Growth
- TOPS N/A
- RLYB N/A
- EPS
- TOPS 1.09
- RLYB N/A
- Revenue
- TOPS $86,127,000.00
- RLYB $761,000.00
- Revenue This Year
- TOPS $9.90
- RLYB N/A
- Revenue Next Year
- TOPS N/A
- RLYB N/A
- P/E Ratio
- TOPS $5.26
- RLYB N/A
- Revenue Growth
- TOPS 3.83
- RLYB 154.51
- 52 Week Low
- TOPS $5.00
- RLYB $0.22
- 52 Week High
- TOPS $11.47
- RLYB $1.25
- Technical
- Relative Strength Index (RSI)
- TOPS 48.69
- RLYB 53.99
- Support Level
- TOPS $5.65
- RLYB $0.47
- Resistance Level
- TOPS $6.28
- RLYB $0.57
- Average True Range (ATR)
- TOPS 0.41
- RLYB 0.06
- MACD
- TOPS -0.01
- RLYB -0.00
- Stochastic Oscillator
- TOPS 48.48
- RLYB 43.23
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.